Overview

Treatment of Pediatric Hypertension With Altace Trial

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Treatments:
Ramipril